Login
Communauté Vinci
Extérieur
Si votre nom d'utilisateur ne se termine pas par @vinci.be ou @student.vinci.be, utilisez le formulaire ci-dessous pour accéder à votre compte de lecteur.
Titre : | Real-life outcomes with ponatinib : results of a nationwide Belgian registry (2020) |
Auteurs : | Koen Theunissen |
Type de document : | Article |
Dans : | Onco Hemato (Vol. 14, n° 1, Février - Mars 2020) |
Article en page(s) : | p. 28-29 |
Langues: | Français |
Descripteurs : |
HE Vinci Belgique ; Chromosome philadelphie ; Etude clinique ; Leucemie lymphoblastique aigue ; Ponatinib |
Mots-clés: | Tyrosine kinase inhibitor |
Résumé : |
Tyrosine kinase inhibitors (TKI) directed against the BCR-ABL fusion protein have revolutionized the treatment of patients with chronic myeloid leukemia (CML) and of acute lymphoblastic leukemia (ALL) patients harboring a Philedalphia chromosome (Ph+). While these agents are associated with high response rates, a small but revelant fraction of patients develops clinical resistance to the BCR-ABL TKI they receive.
The most common mechanism underlying this resistance relates to the development of mutations in the TKI binding domain of the BCR-ABL fusion gene. Increased insights into these acquired resistance mechanisms formed the basis for the development of ponatinib, a third generation BCR-ABL TKI that remains effective in the presence of awide range of BCR-ABL resistance mutations (including the T315I mutation). In the pivotal PACE trial, long-term efficacy and safety data were demonstrated with ponatinib in a population of heaviky pre-treated CML or Ph+ ALL patients. In order to evaluate to what extent the PACE results obtained in the controlled setting of randomized controlled trial translate to the daily clinical practice, it is important to collect real-life data. In addition to this, real-world studies also reveal insights into the treatment patterns in routine practice. In this light, a prospective registry was set up to collect on CML and Ph+ ALL patients treated with ponatinib in twenty Belgian hospitals. During the 2019 annual meeting of the American Society of Hematology (ASH). Dr Koen Theunissen (Jessa Ziekenhuis, Hasselt) presented three-year follow data of this registry. |
Disponible en ligne : | Non |
Exemplaires (1)
Cote | Support | Localisation | Section | Disponibilité |
---|---|---|---|---|
Onco Hemato. vol. 14, n°1 (Février - Mars 2020) | Périodique papier | Woluwe | Espace revues | Consultation sur place uniquement Exclu du prêt |